GM-CSF-loaded chitosan hydrogel as an immunoadjuvant enhances antigen-specific immune responses with reduced toxicity

BMC Immunology

Tae Woo Kim⁴  Hee Dong Han¹  Seung-Yong Seong³  Kyung-Mi Lee⁴  Byung Cheol Shin⁵  In Duk Jung¹  Hat Nim Jeon¹  Yeongseon Byeon¹  Young-Ho Lee⁴  Kwon-Ho Song⁴  Tae Heung Kang¹  Hyuk Soon Kim²  Yeong Min Park¹  Kyung Hee Noh⁴ 

[1] Department of Immunology, School of Medicine, Konkuk University, 268 Chungwondaero, Chungju-Si 380-701, Chungcheongbuk-Do, South Korea;Department of Immunology and Physiology and Functional Genomics Institute, College of Medicine, Konkuk University, 268 Chungwondaero, Chungju-Si 380-701, Chungcheongbuk-Do, South Korea;Department of Biomedical Sciences, College of Medicine, Seoul National University, 28 Yongon-dong, Seoul 110-799, Jongno-gu, Republic of Korea;Department of Biochemistry, College of Medicine, Korea University, Seoul, Korea;Research Center for Medicinal Chemistry, Division of Drug Discovery Research, Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Daejeon 305-600, Yuseong-gu, South Korea

关键词: Immune response;    Hydrogel;    Chitosan;    Adjuvant;   

Others  :  1077691
DOI  :  10.1186/s12865-014-0048-x

 received in 2014-05-19, accepted in 2014-10-10,  发布年份 2014

【 摘 要 】

Background

The application of vaccine adjuvants has been vigorously studied for a diverse range of diseases in order to improve immune responses and reduce toxicity. However, most adjuvants have limited uses in clinical practice due to their toxicity.

Methods

Therefore, to reduce health risks associated with the use of such adjuvants, we developed an advanced non-toxic adjuvant utilizing biodegradable chitosan hydrogel (CH-HG) containing ovalbumin (OVA) and granulocyte-macrophage colony-stimulating factor (GM-CSF) as a local antigen delivery system.

Results

After subcutaneous injection into mice, OVA/GM-CSF-loaded CH-HG demonstrated improved safety and enhanced OVA-specific antibody production compared to oil-based adjuvants such as Complete Freund’s adjuvant (CFA) or Incomplete Freund’s adjuvant (IFA). Moreover, CH-HG system-mediated immune responses was characterized by increased number of OVA-specific CD4⁺ and CD8⁺ INF-γ⁺ T cells, leading to enhanced humoral and cellular immunity.

Conclusions

In this study, the improved safety and enhanced immune response characteristics of our novel adjuvant system suggest the possibility of the extended use of adjuvants in clinical practice with reduced apprehension about toxic side effects.

【 授权许可】

   
2014 Noh et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Wilson-Welder JH, Torres MP, Kipper MJ, Mallapragada SK, Wannemuehler MJ, Narasimhan B: Vaccine adjuvants: current challenges and future approaches. J Pharm Sci 2009, 98(4):1278-1316.
• [2]Riese P, Schulze K, Ebensen T, Prochnow B, Guzman CA: Vaccine adjuvants: key tools for innovative vaccine design. Curr Top Med Chem 2013, 13(20):2562-2580.
• [3]Reed SG, Orr MT, Fox CB: Key roles of adjuvants in modern vaccines. Nat Med 2013, 19(12):1597-1608.
• [4]Chapel HM, August PJ: Report of nine cases of accidental injury to man with Freund's complete adjuvant. Clin Exp Immunol 1976, 24(3):538-541.
• [5]Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, Offringa R, van der Burg SH: CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol 2007, 179(8):5033-5040.
• [6]Stewart-Tull DE: Freund's complete and incomplete adjuvants, preparation, and quality control standards for experimental laboratory animals use. Methods Mol Biol 2010, 626:59-72.
• [7]Seo SH, Han HD, Noh KH, Kim TW, Son SW: Chitosan hydrogel containing GMCSF and a cancer drug exerts synergistic anti-tumor effects via the induction of CD8+ T cell-mediated anti-tumor immunity. Clin Exp Metastasis 2009, 26(3):179-187.
• [8]Han HD, Mora EM, Roh JW, Nishimura M, Lee SJ, Stone RL, Bar-Eli M, Lopez-Berestein G, Sood AK: Chitosan hydrogel for localized gene silencing. Cancer Biol Ther 2011, 11(9):839-845.
• [9]Han HD, Nam DE, Seo DH, Kim TW, Shin BC: Preparation and biodegradation of thermosensitive chitosan hydrogel as a function of pH and temperature. Macromol Res 2004, 12:507-511.
• [10]Zhang C, Wang B, Wang M: GM-CSF and IL-2 as adjuvant enhance the immune effect of protein vaccine against foot-and-mouth disease.Virol J 2011, 8:7.
• [11]Ullenhag GJ, Frodin JE, Strigard K, Mellstedt H, Magnusson CG: Induction of IgG subclass responses in colorectal carcinoma patients vaccinated with recombinant carcinoembryonic antigen. Cancer Res 2002, 62(5):1364-1369.
• [12]Disis ML, Bernhard H, Shiota FM, Hand SL, Gralow JR, Huseby ES, Gillis S, Cheever MA: Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 1996, 88(1):202-210.
• [13]Morrissey PJ, Bressler L, Park LS, Alpert A, Gillis S: Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells. J Immunol 1987, 139(4):1113-1119.
• [14]Sun X, Hodge LM, Jones HP, Tabor L, Simecka JW: Co-expression of granulocyte-macrophage colony-stimulating factor with antigen enhances humoral and tumor immunity after DNA vaccination. Vaccine 2002, 20(9–10):1466-1474.
• [15]Toubaji A, Hill S, Terabe M, Qian J, Floyd T, Simpson RM, Berzofsky JA, Khleif SN: The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection. Vaccine 2007, 25(31):5882-5891.
• [16]Reid CD, Stackpoole A, Meager A, Tikerpae J: Interactions of tumor necrosis factor with granulocyte-macrophage colony-stimulating factor and other cytokines in the regulation of dendritic cell growth in vitro from early bipotent CD34+ progenitors in human bone marrow. J Immunol 1992, 149(8):2681-2688.
• [17]Golumbek PT, Azhari R, Jaffee EM, Levitsky HI, Lazenby A, Leong K, Pardoll DM: Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res 1993, 53(24):5841-5844.
• [18]Igartua M, Hernandez RM, Esquisabel A, Gascon AR, Calvo MB, Pedraz JL: Enhanced immune response after subcutaneous and oral immunization with biodegradable PLGA microspheres. J Control Release 1998, 56(1–3):63-73.
• [19]Chesson CB, Huelsmann EJ, Lacek AT, Kohlhapp FJ, Webb MF, Nabatiyan A, Zloza A, Rudra JS: Antigenic peptide nanofibers elicit adjuvant-free CD8(+) T cell responses. Vaccine 2014, 32(10):1174-1180.
• [20]Xu Y, Tang H, Liu JH, Wang H, Liu Y: Evaluation of the adjuvant effect of silver nanoparticles both in vitro and in vivo. Toxicol Lett 2013, 219(1):42-48.
• [21]Vono M, Taccone M, Caccin P, Gallotta M, Donvito G, Falzoni S, Palmieri E, Pallaoro M, Rappuoli R, Di Virgilio F, De Gregorio E, Montecucco C, Seubert A: The adjuvant MF59 induces ATP release from muscle that potentiates response to vaccination. Proc Natl Acad Sci U S A 2013, 110(52):21095-21100.